Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits

Journal of Cardiovascular Disease Research

Volumn 3, Issue 1, 2012, Pages 5-11

  Hadi, Najah ^a   Al Amran, Fadhil ^a   Mohammad Hussein, A ^a   Rezeg, Fadhil ^a  

^a UNIVERSITY OF KUFA   (Iraq)

Author keywords

Atherosclerosis; glimepiride; inflammatory markers; oxidative stress; repaglinide

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLIMEPIRIDE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; REPAGLINIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; HEART PROTECTION; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84856451406     PISSN: 09753583     EISSN: 09762833     Source Type: Journal    
DOI: 10.4103/0975-3583.91592     Document Type: Article

References (29)

1. Lehto S, Ronnemaa T, Haffner SM. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle aged patients with NIDDM. Diabetes 1997;46:1354-9. (Pubitemid 27315286)
2. Dixon JL, Shen S, Vuchetich JP, Wysocka E, Sun GY, Sturek M. Increased atherosclerosis in diabetic dyslipidemic swine; protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J Lipid Res 2002;43:1618-29. (Pubitemid 35168276)
3. Libby P, Ridker PM. Inflammation and atherosclerosis. Circulation 2002;105:1135-43. (Pubitemid 34212626)
4. Dandona P, Dhindsa S, Ghanim H. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21:20-7. (Pubitemid 44921816)
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
6. Geisen K. Special pharmacology of the new sulfonylurea glimepiride.Arzneim-Forsch/Drug Res 1988;38:1120-30.
7. Langtry H, Balfour J. Glimepiride - A review of its use in the managementof type 2 diabetes mellitus. Drugs 1998;55:563-84. (Pubitemid 28162078)
8. Qi R, Ozaki Y, Satoh K. Sulphonylurea agents inhibit platelet aggregation and [Ca2+]i elevation induced by arachidonic acid. Biochem Pharmacol 1995;49:1735-9.
9. Marquie G. Preventive effect of gliclazide on experimental atherosclerosis in rabbits. Diabetologia 1978;14:269-75. (Pubitemid 8300432)
10. Paasikivi J, Walhlberg F. Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 1971;7:323-7.
11. Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabetic Complications 2001;15(Suppl. 1):68.
12. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998;13:173-80.
13. Tankova T, Koev DK, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2003;59:43-9. (Pubitemid 35461909)
14. Wolffenbuttel BH. Repaglinide- a new compound for the treatment of patients with type 2 diabetes. Netherlands J Med 1999;55:229-34. (Pubitemid 29502442)
15. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005;28:366-71. (Pubitemid 40170941)
16. Shakuto S, Oshima K, Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2005;182: 209-17. (Pubitemid 41267188)
17. Gumieniczek A, Hopka?a H, Roli'nski J, Bojarska-Junak A. Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacol Res 2005;52:162-6. (Pubitemid 40828367)
18. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002;287:2570-81. (Pubitemid 34517204)
19. Muller G, Jung C, Wied S, Welte S, Frick W. Insulin-mimetic signaling by the sulfonylurea glimepiride and phosphoinositolglycans involves distinct mechanisms for redistribution of lipid raft components. Biochemistry 2001;40:14603-20. (Pubitemid 33111744)
20. Maejima Y, Ueba H, Kuroki M. Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis 2003;167:89-95. (Pubitemid 36255639)
21. Kenyon NJ, Vandervliet A, Schock BC, Okamoto T, Mcgrew GM, Last JA. Susceptibility to ozone induce dacute lung injury in iNOS-deficient mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L540-5. (Pubitemid 34654659)
22. Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, et al. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008:28:315-21. (Pubitemid 351161205)
23. Schiekofer S, Rudofsky Jr G, Andrassy M, Schneider J, Chen J, Isermann B, et al. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. Diabetes Obes Metab 2003;5:251-61. (Pubitemid 36806129)
24. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005:280:23653-9. (Pubitemid 40884846)
25. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-9. (Pubitemid 23132154)
26. Stosic-Grujicic SD, Miljkovic DM, Cvetkovic ID, Maksimovic-Ivanic DD, Trajkovic V. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J Autoimmun 2004;22:267-76. (Pubitemid 38548857)
27. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation 2002;106:2067-72. (Pubitemid 35192812)
28. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2003;59:43-9. (Pubitemid 35461909)
29. Baderschneider B, Winterhalter P, Isolation and characterization of novel benzoates, cinnamates, flavonoids and ligands from Riesling wine and screening for antioxidant activity. J Agric Food Chem 2001;49;2278-98.